top of page
Search
Dagny

Politically Convenient Mass Hysteria?


Just how real is the pandemic, and how politically motivated is it?

The former head of Pfizer Research says that the Pfizer Covid-19 vaccine could make women infertile.


(That certainly fits with what Gates has been talking about and apparently trying to do for decades - make women infertile to depopulate the Earth.)


In breaking news today, the U.K. became the first country to issue emergency authorization for Pfizer’s new COVID vaccine, with the first doses being delivered “immediately” and injections expected to begin in the U.K. next week.


Pfizer and BioNTech have made history. The two companies’ BNT162b2 has become the first COVID-19 vaccine allowed in the Western world as drug regulators in the U.K. doled out an emergency use authorization on Wednesday, ahead of decisions by the U.S. and Europe, which are expected soon. For the broader vaccine world, the Medicines and Healthcare products Regulatory Agency’s decision means the world now has the first mRNA shot authorized for widespread use, opening up a brand-new chapter for vaccine development. (Source.)


This announcement today comes one day AFTER an emergency STAY OF ACTION was filed with the European Medicines Agency by Dr. Wolfgang Wodarg and Dr. Michael Yeadon, the former head of Pfizer research.


This STAY OF ACTION is very similar to the one filed last week with the FDA in the U.S. by Dr. Sin Hang Lee, and demands that clinical trials be STOPPED until there is an accurate testing mechanism in place to correctly identify SARS-CoV-2, since the PCR test is very inaccurate.



Dr. Yeadon, the former head of Pfizer research, also went public recently in a viral video recording where he states that the COVID Pandemic is over, and that it is being kept alive by false narratives using the faulty PCR tests.



Yeadon said in the interview:

"Were it not for the test data that you get from the TV all the time, you would rightly conclude that the pandemic was over, as nothing much has happened. Of course people go to the hospital, moving into the autumn flu season...but there is no science to suggest a second wave should happen."

In a paper published this month, which was co-authored by Yeadon and two of his colleagues, "How Likely is a Second Wave?", the scientists write:

"It has widely been observed that in all heavily infected countries in Europe and several of the US states likewise, that the shape of the daily deaths vs. time curves is similar to ours in the UK. Many of these curves are not just similar, but almost super imposable."

Consider the presenter’s bio:


Dr. Michael Yeadon is an Allergy & Respiratory Therapeutic Area expert with 23 years in the pharmaceutical industry. He trained as a biochemist and pharmacologist, obtaining his PhD from the University of Surrey (UK) in 1988. Dr. Yeadon then worked at the Wellcome Research Labs with Salvador Moncada with a research focus on airway hyper-responsiveness and effects of pollutants including ozone and working in drug discovery of 5-LO, COX, PAF, NO and lung inflammation. With colleagues, he was the first to detect exhaled NO in animals and later to induce NOS in lung via allergic triggers.

Joining Pfizer in 1995, he was responsible for the growth and portfolio delivery of the Allergy & Respiratory pipeline within the company. He was responsible for target selection and the progress into humans of new molecules, leading teams of up to 200 staff across all disciplines and won an Achievement Award for productivity in 2008.

Under his leadership the research unit invented oral and inhaled NCEs which delivered multiple positive clinical proofs of concept in asthma, allergic rhinitis and COPD. He led productive collaborations such as with Rigel Pharmaceuticals (SYK inhibitors) and was involved in the licensing of Spiriva and acquisition of the Meridica (inhaler device) company. Dr. Yeadon has published over 40 original research articles and now consults and partners with a number of biotechnology companies. Before working with Apellis, Dr. Yeadon was VP and Chief Scientific Officer (Allergy & Respiratory Research) with Pfizer.



In their STAY OF ACTION filed yesterday, one day BEFORE the U.K. issued emergency use authorization, Dr. Yeadon stated that this vaccine can make females infertile.


He writes that the Pfizer COVID vaccine as well as other COVID vaccines currently in Phase III trials are:


"expected to induce the formation of humoral antibodies against spike proteins of SARS-CoV-2. Syncytin-1 (see Gallaher, B., “Response to nCoV2019 Against Backdrop of Endogenous Retroviruses” – http://virological.org/t/response-to-ncov2019-against-backdrop-of-endogenous-retroviruses/396), which is derived from human endogenous retroviruses (HERV) and is responsible for the development of a placenta in mammals and humans and is therefore an essential prerequisite for a successful pregnancy, is also found in homologous form in the spike proteins of SARS viruses.

There is no indication whether antibodies against spike proteins of SARS viruses would also act like anti-Syncytin-1 antibodies. However, if this were to be the case this would then also prevent the formation of a placenta which would result in vaccinated women essentially becoming infertile.

To my knowledge, Pfizer/BioNTech has yet to release any samples of written materials provided to patients, so it is unclear what, if any, information regarding (potential) fertility-specific risks caused by antibodies is included.

According to section 10.4.2 of the Pfizer/BioNTech trial protocol, a woman of childbearing potential (WOCBP) is eligible to participate if she is not pregnant or breastfeeding, and is using an acceptable contraceptive method as described in the trial protocol during the intervention period (for a minimum of 28 days after the last dose of study intervention).

This means that it could take a relatively long time before a noticeable number of cases of postvaccination infertility could be observed. "




Landmark Study Finds Masks Are Ineffective


Analysis by Dr. Joseph Mercola

  • The first randomized controlled trial of more than 6,000 individuals to assess the effectiveness of surgical face masks against SARS-CoV-2 infection found masks did not statistically significantly reduce the incidence of infection

  • Among mask wearers, 1.8% ended up testing positive for SARS-CoV-2, compared to 2.1% among controls. When they removed the people who did not adhere to proper mask use, the results remained the same — 1.8%, which suggests adherence makes no significant difference

  • Among those who reported wearing their face mask “exactly as instructed,” 2% tested positive for SARS-CoV-2 compared to 2.1% of the controls

  • 1.4% tested positive for antibodies at the end of the month-long study compared to 1.8% of controls

  • 0.5% in the mask group and 0.6% tested positive for one or more respiratory viruses other than SARS-CoV-2

More interesting details are here:


*************************************************************************

Mass hysteria

In sociology and psychology, mass hysteria is a phenomenon that transmits collective illusions of threats, whether real or imaginary, through a population in society as a result of rumors and fear.


The Democrats and legacy media are responsible for intentionally pushing a mass hysteria.

*************************************************************************


Personal opinion:

It looks like wearing a mask may have a tiny benefit. I suspect it has the Dumbo the elephant Effect at work. Remember the Story of Dumbo the Elephant? He actually could fly, but didn't believe it so he was given a "magic feather". He then was able to fly. When he lost his feather he almost crashed, but realized he could fly on his own just in time to avert the impact.


When people have a mask they feel safe, and they take more chances. They fly. They are less stressed. Taking more chances would increase risk, but feeling safe would reduce risk by helping the immune system function. It seems to balance out.


98 views0 comments

Recent Posts

See All

Comments


bottom of page